



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al.) Group Art Unit: Unknown
App. No. : 09/978,375)
Filed : October 16, 2001)
For : SECRETED AND)
TRANSMEMBRANE)
POLYPEPTIDES AND)
NUCLEIC ACIDS ENCODING)
THE SAME)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202


Dear Sir:

Enclosed is form PTO-1449 listing 2 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP


Dated: April 15, 2002

By: 
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GNE 2630P1C24

APPLICATION NO. 09 978 375

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Ashkenazi et alFILING DATE
October 16, 2001GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Blast Results A1-A7 (Alignment of DNA39523 and various nucleotide sequences - GenBank Database). October 4, 2001
	2	Blast Results B1-B5 (Alignment of DNA39523 and various polypeptide sequences - Dayhoff Database). October 3, 2001
	3	
	4	

W:\DOCS\BGY\BGY-2183.DOC
041202

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	